Penambahan Ciprofloksacin Intravena terhadap Ceftriakson sebagai Terapi Antibiotik Empiris pada Pasien Pneumonia Rawat Inap: Perbandingan Biaya dan Efektivitas

Abstract

In clinical practices the aim of adding antibiotics treatment was to improve the outcomes. The objective of this study was to assess whether adding intravenous ciprofloxacin could bear more benefit despite the cost of treatment than that of intravenous ceftriaxone for hospitalized pneumonia. This retrospective study devided patients with pneumonia into two groups; first, patients received intravenous ceftriaxone therapy only (CTX group), second, patients received combination of intravenous ceftriaxone plus ciprofloxacin (CTXCP group). There were 171 patients recruited, 106 patients received CTX treatment and 65 patients received CTXCP. The data were matched between groups by age, gender, level of payment and comorbidities. The total cost of treating hospitalized pneumonia with CTXCP was higher than CTX (p=0,000). Meanwhile, the length of stay (LOS) and length of stay antbiotic related (LOSAR) were shorter in CTX group than CTXCP (11,32 vs 13,15 days, p=0,14 and 9,26 vs 12,09 days, p=0,000). Moreover, the success rate and first line clinal failure avoided (CFA) in CTX group were better than CTXCP (81,13% vs 66,15%, p=0,027 and 71,79% vs 44,62%, p=0,000). This research concluded that adding ciprofloxacin intravenous as empiric treatment of hospitalized pneumonia did not improve outcomes but significantly increased the cost of treatment.